scholarly journals Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer

2019 ◽  
Vol 6 (2) ◽  
pp. 12
Author(s):  
Shuna S ◽  
Ping L ◽  
Junfei W
Keyword(s):  
Ovarian Cancer ◽  
Matrix Metalloproteinase ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Expression Levels ◽  
Benign Ovarian Tumor ◽  
Significant Difference ◽  
Malignant Ovarian Tumor ◽  
Serum Ca125 ◽  
The Difference

Objective: To explore the expression levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods: ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor, and RIA was used to detect the expression level of CA125 in the serum in these patients.Results: The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor (t = 8.08, 10.39, p < .01), and the difference was of statistical significance. The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors, and the difference was statistically significant (t = 2.75, 2.75, p < .05). There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types, different histological grades, lymph node metastasis or not, different ascites volumes and different residual lesions (p > .05). The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0% and 88.0%, respectively, which were significantly higher than those of ascites cytological examinations (χ2 = 4.61, 12.74, p < .05), but in comparison with serum CA125, there was no statistically significant difference (p > .05). The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3% and 82.6%, respectively, which were significantly lower than those of ascites cytological examinations (χ2 = 5.61, 4.38, p < .05), but in comparison with serum CA125, there was no statistically significant difference (χ2 = 1.64, 2.68, p < .05).Conclusions: The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions, and they are related to the prognosis in patients with malignant ovarian tumors.

scholarly journals Metagenomic Analysis of Serum Microbe-Derived Extracellular Vesicles and Diagnostic Models to Differentiate Ovarian Cancer and Benign Ovarian Tumor

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1309 ◽  
Author(s):  
Se Ik Kim ◽  
Nayeon Kang ◽  
Sangseob Leem ◽  
Jinho Yang ◽  
HyunA Jo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Vesicles ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Metagenomic Analysis ◽  
Serum Samples ◽  
Benign Ovarian Tumor ◽  
Diagnostic Models ◽  
Test Sets ◽  
Benign Ovarian Tumors

We aimed to develop a diagnostic model identifying ovarian cancer (OC) from benign ovarian tumors using metagenomic data from serum microbe-derived extracellular vesicles (EVs). We obtained serum samples from 166 patients with pathologically confirmed OC and 76 patients with benign ovarian tumors. For model construction and validation, samples were randomly divided into training and test sets in the ratio 2:1. Isolation of microbial EVs from serum samples of the patients and 16S rDNA amplicon sequencing were carried out. Metagenomic and clinicopathologic data-based OC diagnostic models were constructed in the training set and then validated in the test set. There were significant differences in the metagenomic profiles between the OC and benign ovarian tumor groups; specifically, genus Acinetobacter was significantly more abundant in the OC group. More importantly, Acinetobacter was the only common genus identified by seven different statistical analysis methods. Among the various metagenomic and clinicopathologic data-based OC diagnostic models, the model consisting of age, serum CA-125 levels, and relative abundance of Acinetobacter showed the best diagnostic performance with the area under the receiver operating characteristic curve of 0.898 and 0.846 in the training and test sets, respectively. Thus, our findings establish a metagenomic analysis of serum microbe-derived EVs as a potential tool for the diagnosis of OC.

scholarly journals CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Zhiheng Wang ◽  
Xiang Tao ◽  
Chunmei Ying
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Menopausal Status ◽  
Ovarian Tumors ◽  
Cancer Antigen 125 ◽  
Borderline Ovarian Tumors ◽  
Early Stages ◽  
Pathological Subtype ◽  
Benign Ovarian Tumor ◽  
Significant Difference

Aim. To evaluate the diagnosis value of serum human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the Risk of Ovarian Malignancy Algorithm (ROMA), and Copenhagen Index (CPH-I) at early stages for differentiating borderline ovarian tumors from epithelial ovarian cancer. Methods. We recruited 144 borderline ovarian tumors in FIGO stages I and II (BOT I+II), 108 epithelial ovarian cancers in FIGO stages I and II (EOC I+II), and 238 benign ovarian tumor patients with surgical treatment in the retrospective study. The concentration of HE4 and CA125 and the values of CPH-I and ROMA were assessed separately. Results. The HE4 level and ROMA and CPH-I values of EOC I+II were all higher than that of BOT I+II and benign groups whether in all, pre-, or postmenopausal groups (P<0.01). When distinguishing BOT I+II from EOC I+II, the AUC-ROC of CPH-I and HE4 were bigger than CA125 (P<0.001), while the CPH-I has the highest sensitivities in all and postmenopausal groups (78.7%, 85.1%), and HE4 has the highest specificity and PPV (90.91%, 88.64%) in postmenopausal groups. Under pathological stratification, HE4, ROMA, and CPH-I of the serous EOC I+II were higher than that of BOT I+II (P<0.001) and the AUC of the three indices were significantly bigger than CA125 (P<0.001). However, the concentration of HE4 and CA125 and the values of CPH-I and ROMA have no significant difference between the two endometrioid subgroups. The index with the highest sensitivity and NPV among the four indices of different pathological subtype groups was CPH-I, and the index with the highest specificities and PPV was HE4. Conclusion. CPH-I was more valuable than CA125 for differentiating BOT I+II from EOC I+II regardless of menopausal status, while HE4 might be better than CA125 for postmenopausal subgroups. HE4 and CPH-I were more favorable than CA125 for differentiating BOT I+II from EOC I+II in the case of unknown pathology or in serous type.

TUMOR GANAS OVARIUM RESIDIF METASTASIS KARSINOMA MUSIN KE UMBILIKUS, PERITONEUM, DAN CAIRAN ASITES TANPA DITEMUKAN TANDA KEGANASAN PADA PEMERIKSAAN HISTOPATOLOGIS PASCA OPERATIF SEBELUMNYA

2019 ◽  
Vol 3 (2) ◽  
pp. 130-136
Author(s):  
Arif Fadillah ◽  
Andi Friadi
Keyword(s):  
Ovarian Carcinoma ◽  
Ovarian Tumor ◽  
Malignant Tumors ◽  
Histopathological Examination ◽  
Ovarian Tumors ◽  
Postoperative Chemotherapy ◽  
Definitive Treatment ◽  
Malignant Ovarian Tumor ◽  
Patient Will ◽  
Optimal Debulking

Background : Malignant ovarian tumor are still the number one cause of death and the second most  of incidents for gynecological malignant tumors. The principles of management of ovarian cancer are the same as the principles of handling other malignant diseases, for the treatment of primary lesions operatively and the handling of potential sites of tumor metastases with chemotherapy. Histopathological examination is still considered a gold standard for diagnosis and definitive treatment of malignant ovarian tumors. If histopathologic results are obtained, then the patient will be planned to undergo postoperative chemotherapy. The mismatch between the preoperative and intraoperative clinical features, and the results of postoperative histopathological examination is a problem in managing cases of ovarian malignant tumors.Objective : Report a case of residive ovarian carcinoma with no appearance of malignancy marker in the previous postoperative histopathological examination.Method : Case reportCase : We report the case of a 45-year-old woman with a history of two previous laparotomy. The first operation was carried out in February 2014 on the indication of an extra ovarian cyst, resulting in the impression of a "Follicular Cysts" based on histopathological examination. The second operation was performed in March 2015, performed surgical staging tumors with an indication of malignant ovarian tumors with clinical metastases, but from histopathological examination it was found that "Cystadenoma Ovarii Muscinosum Multiloculare" and "no visible signs of malignancy", so the patient was not managed with postoperative chemotherapy. In April 2019 patients came with complaints of new mass growth, from CT-Scan and USG investigations there was a suspicious impression of a residive ovarian tumor with metastases into the omentum and massive ascites. On May 16, 2019 an optimal debulking was performed with the findings of residive mass, ascites, and mass metastases in the intra operative peritoneum. From the results of histopathological examination, it was found that "Muscinous Carcinoma with metastases to the umbilicus, peritoneum, and ascitic fluidKeywords: Malignant residive ovarian tumor, mucinous ovarian carcinoma

Serum SELDI-TOF MS analysis model applied to benign and malignant ovarian tumor identification

2016 ◽  
Vol 8 (1) ◽  
pp. 183-188 ◽  
Author(s):  
Yankun Li ◽  
Xiangchao Zeng
Keyword(s):  
Ovarian Tumor ◽  
Analysis Model ◽  
Pattern Recognition Technique ◽  
Serum Peptide ◽  
Tumor Identification ◽  
Benign Ovarian Tumor ◽  
Malignant Ovarian Tumor ◽  
Peptide Profiles ◽  
Recognition Technique ◽  
Tof Ms

SELDI-TOF MS serum peptide profiles of malignant and benign ovarian tumor samples were studied using a pattern recognition technique.

scholarly journals The effect of prophylactic bilateral salpingectomy on ovarian reserve in patients who underwent laparoscopic hysterectomy

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Shizhuo Wang ◽  
Jiahui Gu
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Reserve ◽  
Premenopausal Women ◽  
Laparoscopic Hysterectomy ◽  
Ovarian Tumors ◽  
Reproductive Age ◽  
Control Group ◽  
Significant Difference ◽  
Bilateral Salpingectomy ◽  
The Impact

Abstract Background Bilateral salpingectomy has been proposed to reduce the risk of ovarian cancer, but it is not clear whether the surgery affects ovarian reserve. This study compares the impact of laparoscopic hysterectomy for benign disease with or without prophylactic bilateral salpingectomy on ovarian reserve. Methods Records were reviewed for 373 premenopausal women who underwent laparoscopic hysterectomy with ovarian reserve for benign uterine diseases. The serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and three-dimensional antral follicle count (AFC) were assessed before surgery and 3 and 9 months postoperatively to evaluate ovarian reserve. Patients were divided into two groups according to whether they underwent prophylactic bilateral salpingectomy. The incidence of pelvic diseases was monitored until the ninth month after surgery. Results There was no significant difference between the two surgery groups in terms of baseline AMH, E2, FSH, LH, and AFC (all P > 0.05). There was no difference in potential bias factors, including patient age, operative time, and blood loss (all P > 0.05). There was also no significant difference between the two groups 3 months after surgery with respect to AMH (P = 0.763), E2 (P = 0.264), FSH (P = 0.478), LH (P = 0.07), and AFC (P = 0.061). Similarly, there were no differences between groups 9 months after surgery for AMH (P = 0.939), E2 (P = 0.137), FSH (P = 0.276), LH (P = 0.07) and AFC (P = 0.066). At 9 months after the operation, no patients had malignant ovarian tumors. The incidences of benign ovarian tumors in the salpingectomy group were 0 and 2.68 % at 3 and 9 months after surgery, respectively, and the corresponding values in the control group were 0 and 5.36 %. The incidences of pelvic inflammatory disease in the salpingectomy group were 10.72 and 8.04 % at 3 and 9 months after surgery, respectively, while corresponding values in the control group were 24.13 and 16.09 %. Conclusions Prophylactic bilateral salpingectomy did not damage the ovarian reserve of reproductive-age women who underwent laparoscopic hysterectomy. Prophylactic bilateral salpingectomy might be a good method to prevent the development of ovarian cancer. Larger clinical trials with longer follow-up times are needed to further evaluate the risks and benefits.

Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues

1997 ◽  
Vol 120 (1) ◽  
pp. 109-115 ◽  
Author(s):  
Fumitaka Kikkawa ◽  
Koji Tamakoshi ◽  
Akihiro Nawa ◽  
Kiyosumi Shibata ◽  
Sadako Yamagata ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Matrix Metalloproteinase ◽  
Ovarian Tumor ◽  
Positive Correlation ◽  
Matrix Metalloproteinase 1 ◽  
Tumor Tissues ◽  
Malignant Ovarian Tumor

scholarly journals Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study

2020 ◽  
Vol Volume 12 ◽  
pp. 637-649 ◽  
Author(s):  
Chen-Yu Huang ◽  
Wen-Hsun Chang ◽  
Hsin-Yi Huang ◽  
Chao-Yu Guo ◽  
Yiing-Jenq Chou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumor ◽  
Subsequent Development ◽  
Population Based ◽  
Benign Ovarian Tumor ◽  
Ovarian Surgery

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

2002 ◽  
Vol 20 (2) ◽  
pp. 463-466 ◽  
Author(s):  
Y. Ben David ◽  
A. Chetrit ◽  
G. Hirsh-Yechezkel ◽  
E. Friedman ◽  
B.D. Beck ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Cox Regression ◽  
Ovarian Tumors ◽  
Early Years ◽  
Rank Test ◽  
Brca Mutations ◽  
Blood Samples ◽  
Cox Regression Analysis ◽  
Significant Difference

PURPOSE: To study the role of BRCA mutations in ovarian cancer survival. PATIENTS AND METHODS: Blood samples and specimens of ovarian tumors (whenever blood samples were not available) at the time of the primary surgery were obtained in the course of a nationwide case-control study of women with ovarian cancer in Israel. The three common BRCA mutations in Israel (185delAG, 5382insC, and 6174delT) were analyzed with a multiplex polymerase chain reaction to amplify the exons containing the three mutations using fluor-labeled primers in a single reaction. Because each mutation is a small insertion or deletion, they can be detected as length polymorphisms. Patients were followed for up to 5 years (range, 20 to 64 months). Statistical analysis was performed using the Kaplan-Meier method and the log-rank test. Stepwise Cox regression analysis was used for determination of independent prognostic factors. RESULTS: This report is based on 896 blood or tumor specimens analyzed for the presence of the BRCA mutations. Of these, 234 women (26.1%) were found to be positive. A significant difference in survival pattern was found between BRCA1/BRCA2 carriers and noncarriers among the women with invasive ovarian cancer (median survival, 53.4 months v 37.8 months; 3-year survival, 65.8% v 51.9%, respectively). These differences were independent of age at diagnosis or stage of the disease. CONCLUSION: Our data indicate that the survival of patients with ovarian cancer is affected by BRCA germline mutation, at least in the early years after diagnosis.

scholarly journals Survivin and Vegf as Novel Biomarkers in Diagnosis of Endometriosis/ Survivin i vegf kao novi biomarkeri u dijagnostici endometrioze

2016 ◽  
Vol 35 (1) ◽  
pp. 63-68 ◽  
Author(s):  
Milena Acimovic ◽  
Snezana Vidakovic ◽  
Natasa Milic ◽  
Katarina Jeremic ◽  
Milos Markovic ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Peripheral Blood ◽  
Transvaginal Ultrasound ◽  
False Negative ◽  
Diagnostic Tools ◽  
Expression Levels ◽  
Diagnostic Score ◽  
Significant Difference ◽  
Serum Ca125 ◽  
Mrna Expression Levels

Summary Background: The aim of this study was to investigate the role of peripheral blood markers as additional diagnostic tools to transvaginal ultrasound (TVU) findings in the diagnosis of endometriosis. Methods: This study included 40 patients undergoing laparoscopy for suspected endometriosis from January to December 2012. Preoperative levels of serum CA125, CA19-9, CEA and mRNA expression levels for survivin and VEGF were obtained. Real-time PCR was used to determine relative gene expression. A new diagnostic score was obtained by deploying the peripheral blood markers to the TVU findings. Statistical methods used were Chi-square, Fisher’s, Student’s t-test or the Mann - Whitney test. Results: There was a statistically significant difference in serum CA125, survivin and VEGF levels in patients with endometriosis and those without endometriosis (p<0.001, p=0.025 and p=0.009, respectively). False negative TVU findings were noted in 3/13 patients (23.1%) with peritoneal endometriosis without ovaries involvement. High sensitivity (93.3%), specificity (90.0%), PPV (96.6%), NPV (81.8%) and accuracy (92.5%) were obtained for a diagnostic score based on TVU and significant peripheral blood markers (CA125, survivin and VEGF). Conclusions: Determination of serum CA125, mRNA expression levels for survivin and VEGF along with TVU can contribute to higher accuracy of the noninvasive diagnostic tools for endometriosis.

scholarly journals Skin Metastasis from Malignant Ovarian Tumor - A Rare Entity

2016 ◽  
Vol 33 (1) ◽  
pp. 41-43
Author(s):  
TS Chowdhury ◽  
U Ruman ◽  
TA Chowdhury
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Ovarian Tumor ◽  
Skin Metastasis ◽  
Ovarian Malignancy ◽  
Rare Entity ◽  
Malignant Ovarian Tumor ◽  
Previous Laparotomy ◽  
Skin Nodules ◽  
Serous Cyst

Skin metastasis from malignant ovarian carcinoma is rare and seen in only 3% of patients. Hence, we report a case of ovarian cancer with scar metastasis. The patient, a 31 year old woman presented with two skin nodules in the previous laparotomy scar which revealed metastatic papillary serous cyst adenocarcinoma on histopathology. So, it should be considered that ovarian malignancy is not always confined to pelvis and may present with associated skin lesion.J Bangladesh Coll Phys Surg 2015; 33(1): 41-43

Sign in / Sign up

Export Citation Format

Share Document